Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Matinas BioPharma ( (MTNB) ) has issued an update.
On April 2, 2026, Matinas BioPharma received a notice from NYSE American that it is out of compliance with the exchange’s stockholders’ equity listing standards after posting losses in each of the five years through December 31, 2025, when equity stood at $4.83 million. The company is not eligible for an exemption, but its shares remain listed and traded for now as it confronts both the listing deficiency and an auditor’s warning about substantial doubt regarding its ability to continue as a going concern.
Matinas has until May 2, 2026, to submit a compliance plan to NYSE American and could have up to 18 months from the notice date to cure the deficiency if the plan is accepted, during which it would undergo periodic, including quarterly, reviews. If the plan is rejected or the company fails to regain compliance within the cure period, delisting proceedings could begin, a development that would heighten risks for shareholders even though the notice does not currently affect day-to-day operations or SEC reporting obligations.
The most recent analyst rating on (MTNB) stock is a Hold with a $0.48 price target. To see the full list of analyst forecasts on Matinas BioPharma stock, see the MTNB Stock Forecast page.
Spark’s Take on MTNB Stock
According to Spark, TipRanks’ AI Analyst, MTNB is a Neutral.
The score is driven primarily by weak financial fundamentals (no revenue, ongoing losses and cash burn, and a sharply reduced equity base) despite improved 2025 loss and burn trends. Technicals are also unfavorable with the stock below all key moving averages and negative MACD, while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on MTNB stock, click here.
More about Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on developing groundbreaking therapies using its lipid nanocrystal drug-delivery platform. Its lead candidate, MAT2203, is an oral, broad-spectrum formulation of amphotericin B targeting invasive fungal infections, aiming to match fungicidal activity while reducing toxicity and improving treatment options.
Average Trading Volume: 28,795
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.5M
For detailed information about MTNB stock, go to TipRanks’ Stock Analysis page.